Nile Pharmaceuticals results, Q2 2026
Net profit, assets, equity and cash flow for Q2 2026, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit63.55 millionEGP · −19.0% vs the same period a year earlier
Total assets2.83 billionEGP
Shareholders' equity1.04 billionEGP · +113.7% vs the same period a year earlier
In short
- Nile Pharmaceuticals's net profit for Q2 2026 was about 63.55 million EGP, down −19.0% from 78.41 million EGP in Q2 2025.
- Total assets at the end of Q2 2026 were about 2.83 billion EGP, and shareholders' equity about 1.04 billion EGP.
Key lines against the same period a year earlier
This periodQ2 2025Change
Net profit63.55 million78.41 million−19.0%
Gross profit174 million484 million−64.1%
Total assets2.83 billion——
Total liabilities1.79 billion——
Shareholders' equity1.04 billion485 million+113.7%
Total liabilities and equity2.83 billion1.81 billion+56.3%
Operating cash flow—-29.32 million—
Investing cash flow-73.45 million-95.38 million+23.0%
Financing cash flow-563 million129 million−536.1%
Net change in cash———
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Nile Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy